Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to evaluate the Hepatic safety of Febuxostat Compared to Allopurinol in Gout Patients with Fatty Liver Disease

Trial Profile

Study to evaluate the Hepatic safety of Febuxostat Compared to Allopurinol in Gout Patients with Fatty Liver Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Gout
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Nov 2018 New trial record
    • 15 Nov 2018 Results (n=32) assessing the efficacy of febuxostat in gout and fatty liver disease patients, published in The Journal of Rheumatology.
    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top